vs
Revvity（RVTY）与TrueBlue, Inc.（TBI）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是TrueBlue, Inc.的1.8倍（$772.1M vs $418.2M），TrueBlue, Inc.同比增速更快（8.3% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-7.5M），过去两年Revvity的营收复合增速更高（9.0% vs 1.9%）
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
蓝鸟公司是一家美国巴士制造商，总部位于佐治亚州福瓦尔谷。该公司以生产校车闻名于世，除此之外还生产多种其他类型巴士，包括城市公交巴士、房车，以及流动图书馆、移动警务指挥中心等特种车辆。
RVTY vs TBI — 直观对比
营收规模更大
RVTY
是对方的1.8倍
$418.2M
营收增速更快
TBI
高出2.5%
5.9%
自由现金流更多
RVTY
多$169.3M
$-7.5M
两年增速更快
RVTY
近两年复合增速
1.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $772.1M | $418.2M |
| 净利润 | $98.4M | — |
| 毛利率 | — | 21.5% |
| 营业利润率 | 14.5% | -7.0% |
| 净利率 | 12.7% | — |
| 营收同比 | 5.9% | 8.3% |
| 净利润同比 | 3.9% | — |
| 每股收益（稀释后） | $0.86 | $-1.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RVTYTBI
| Q4 25 | $772.1M | $418.2M | ||
| Q3 25 | $698.9M | $431.3M | ||
| Q2 25 | $720.3M | $396.3M | ||
| Q1 25 | $664.8M | $370.3M | ||
| Q4 24 | $729.4M | $386.0M | ||
| Q3 24 | $684.0M | $382.4M | ||
| Q2 24 | $691.7M | $396.2M | ||
| Q1 24 | $649.9M | $402.9M |
净利润RVTYTBI
| Q4 25 | $98.4M | — | ||
| Q3 25 | $46.7M | $-1.9M | ||
| Q2 25 | $53.9M | $-160.0K | ||
| Q1 25 | $42.2M | $-14.3M | ||
| Q4 24 | $94.6M | — | ||
| Q3 24 | $94.4M | $-7.6M | ||
| Q2 24 | $55.4M | $-104.7M | ||
| Q1 24 | $26.0M | $-1.7M |
毛利率RVTYTBI
| Q4 25 | — | 21.5% | ||
| Q3 25 | 53.6% | 22.7% | ||
| Q2 25 | 54.5% | 23.6% | ||
| Q1 25 | 56.5% | 23.3% | ||
| Q4 24 | — | 26.6% | ||
| Q3 24 | 56.3% | 26.2% | ||
| Q2 24 | 55.7% | 26.4% | ||
| Q1 24 | 54.6% | 24.7% |
营业利润率RVTYTBI
| Q4 25 | 14.5% | -7.0% | ||
| Q3 25 | 11.7% | -0.0% | ||
| Q2 25 | 12.6% | -0.7% | ||
| Q1 25 | 10.9% | -3.8% | ||
| Q4 24 | 16.3% | -2.7% | ||
| Q3 24 | 14.3% | -1.8% | ||
| Q2 24 | 12.4% | -15.1% | ||
| Q1 24 | 6.8% | -3.8% |
净利率RVTYTBI
| Q4 25 | 12.7% | — | ||
| Q3 25 | 6.7% | -0.4% | ||
| Q2 25 | 7.5% | -0.0% | ||
| Q1 25 | 6.4% | -3.9% | ||
| Q4 24 | 13.0% | — | ||
| Q3 24 | 13.8% | -2.0% | ||
| Q2 24 | 8.0% | -26.4% | ||
| Q1 24 | 4.0% | -0.4% |
每股收益（稀释后）RVTYTBI
| Q4 25 | $0.86 | $-1.06 | ||
| Q3 25 | $0.40 | $-0.06 | ||
| Q2 25 | $0.46 | $-0.01 | ||
| Q1 25 | $0.35 | $-0.48 | ||
| Q4 24 | $0.77 | $-0.41 | ||
| Q3 24 | $0.77 | $-0.26 | ||
| Q2 24 | $0.45 | $-3.45 | ||
| Q1 24 | $0.21 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $919.9M | $24.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.3B | $274.6M |
| 总资产 | $12.2B | $638.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RVTYTBI
| Q4 25 | $919.9M | $24.5M | ||
| Q3 25 | $931.4M | $19.9M | ||
| Q2 25 | $991.8M | $21.9M | ||
| Q1 25 | $1.1B | $23.1M | ||
| Q4 24 | $1.2B | $22.5M | ||
| Q3 24 | $1.2B | $14.5M | ||
| Q2 24 | $2.0B | $26.4M | ||
| Q1 24 | $1.7B | $36.2M |
股东权益RVTYTBI
| Q4 25 | $7.3B | $274.6M | ||
| Q3 25 | $7.4B | $304.3M | ||
| Q2 25 | $7.6B | $305.2M | ||
| Q1 25 | $7.6B | $302.2M | ||
| Q4 24 | $7.7B | $315.4M | ||
| Q3 24 | $7.9B | $327.2M | ||
| Q2 24 | $7.9B | $337.8M | ||
| Q1 24 | $7.8B | $446.4M |
总资产RVTYTBI
| Q4 25 | $12.2B | $638.7M | ||
| Q3 25 | $12.1B | $690.5M | ||
| Q2 25 | $12.4B | $672.8M | ||
| Q1 25 | $12.4B | $692.5M | ||
| Q4 24 | $12.4B | $675.4M | ||
| Q3 24 | $12.8B | $702.4M | ||
| Q2 24 | $13.4B | $723.7M | ||
| Q1 24 | $13.4B | $868.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $182.0M | $-4.4M |
| 自由现金流经营现金流 - 资本支出 | $161.8M | $-7.5M |
| 自由现金流率自由现金流/营收 | 21.0% | -1.8% |
| 资本支出强度资本支出/营收 | 2.6% | 0.7% |
| 现金转化率经营现金流/净利润 | 1.85× | — |
| 过去12个月自由现金流最近4个季度 | $509.4M | $-73.7M |
8季度趋势，按日历期对齐
经营现金流RVTYTBI
| Q4 25 | $182.0M | $-4.4M | ||
| Q3 25 | $138.5M | $-19.8M | ||
| Q2 25 | $134.3M | $-11.8M | ||
| Q1 25 | $128.2M | $-22.1M | ||
| Q4 24 | $174.2M | $6.1M | ||
| Q3 24 | $147.9M | $-7.1M | ||
| Q2 24 | $158.6M | $-1.8M | ||
| Q1 24 | $147.6M | $-14.2M |
自由现金流RVTYTBI
| Q4 25 | $161.8M | $-7.5M | ||
| Q3 25 | $120.0M | $-23.4M | ||
| Q2 25 | $115.5M | $-16.1M | ||
| Q1 25 | $112.2M | $-26.8M | ||
| Q4 24 | $149.8M | $854.0K | ||
| Q3 24 | $125.6M | $-12.7M | ||
| Q2 24 | $136.6M | $-7.7M | ||
| Q1 24 | $129.7M | $-21.6M |
自由现金流率RVTYTBI
| Q4 25 | 21.0% | -1.8% | ||
| Q3 25 | 17.2% | -5.4% | ||
| Q2 25 | 16.0% | -4.0% | ||
| Q1 25 | 16.9% | -7.2% | ||
| Q4 24 | 20.5% | 0.2% | ||
| Q3 24 | 18.4% | -3.3% | ||
| Q2 24 | 19.7% | -2.0% | ||
| Q1 24 | 20.0% | -5.4% |
资本支出强度RVTYTBI
| Q4 25 | 2.6% | 0.7% | ||
| Q3 25 | 2.6% | 0.8% | ||
| Q2 25 | 2.6% | 1.1% | ||
| Q1 25 | 2.4% | 1.3% | ||
| Q4 24 | 3.4% | 1.4% | ||
| Q3 24 | 3.3% | 1.5% | ||
| Q2 24 | 3.2% | 1.5% | ||
| Q1 24 | 2.7% | 1.8% |
现金转化率RVTYTBI
| Q4 25 | 1.85× | — | ||
| Q3 25 | 2.97× | — | ||
| Q2 25 | 2.49× | — | ||
| Q1 25 | 3.03× | — | ||
| Q4 24 | 1.84× | — | ||
| Q3 24 | 1.57× | — | ||
| Q2 24 | 2.87× | — | ||
| Q1 24 | 5.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
TBI
| People Scout | $187.7M | 45% |
| Other | $175.0M | 42% |
| Healthcare Staffing Professionals Inc. | $55.5M | 13% |
